Notify me when EcoR1 Capital, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 28 | $2,182,086,314 | +$205,453,891 | -$589,161,127 | -$383,707,236 | ZYME, ANAB, JAZZ, CRNX, CNTA | 13F-HR | 17 Feb 2026, 11:53 |
| Q3 2025 | 30 | $2,083,868,932 | +$186,205,838 | -$477,105,100 | -$290,899,262 | ZYME, ANAB, QURE, JAZZ, CRNX | 13F-HR | 14 Nov 2025, 12:15 |
| Q2 2025 | 36 | $1,685,570,229 | +$270,438,134 | -$292,273,097 | -$21,834,963 | ZYME, APLS, JAZZ, ANAB, CRNX | 13F-HR | 14 Aug 2025, 11:04 |
| Q1 2025 | 44 | $1,682,241,027 | +$107,850,939 | -$359,833,032 | -$251,982,093 | APLS, JAZZ, ZYME, ANAB, CRNX | 13F-HR | 15 May 2025, 10:58 |
| Q4 2024 | 55 | $2,496,943,809 | +$329,804,236 | -$372,423,119 | -$42,618,883 | APLS, ZYME, CRNX, JAZZ, PRTA | 13F-HR | 14 Feb 2025, 13:05 |
| Q3 2024 | 63 | $2,917,831,648 | +$254,700,991 | -$669,514,095 | -$414,813,104 | APLS, ANAB, CRNX, PRTA, JAZZ | 13F-HR | 14 Nov 2024, 11:16 |
| Q2 2024 | 55 | $3,266,068,692 | +$258,376,743 | -$257,236,391 | +$1,140,352 | APLS, PRTA, SRPT, ANAB, CRNX | 13F-HR | 14 Aug 2024, 11:37 |
| Q1 2024 | 57 | $3,934,521,996 | +$678,762,858 | -$646,709,389 | +$32,053,469 | APLS, PRTA, ARVN, SRPT, CRNX | 13F-HR | 15 May 2024, 11:45 |
| Q4 2023 | 51 | $3,848,662,050 | +$650,508,210 | -$366,595,832 | +$283,912,378 | APLS, MRTX, PRTA, ARVN, GLPG | 13F-HR | 14 Feb 2024, 11:30 |
| Q3 2023 | 49 | $2,934,024,327 | +$648,347,731 | -$660,069,106 | -$11,721,375 | PRTA, APLS, MRTX, GLPG, RVMD | 13F-HR | 14 Nov 2023, 12:16 |
| Q2 2023 | 51 | $3,792,290,064 | +$432,249,931 | -$152,474,667 | +$279,775,264 | PRTA, APLS, SRPT, GLPG, MORF | 13F-HR | 14 Aug 2023, 11:42 |
| Q1 2023 | 58 | $3,101,975,548 | +$163,473,315 | -$191,627,898 | -$28,154,583 | PRTA, SRPT, APLS, GLPG, ANAB | 13F-HR | 15 May 2023, 12:19 |
| Q4 2022 | 66 | $3,281,950,903 | +$298,254,397 | -$279,961,922 | +$18,292,475 | PRTA, SRPT, APLS, ANAB, GLPG | 13F-HR | 14 Feb 2023, 12:00 |
| Q3 2022 | 75 | $3,385,405,000 | +$313,795,018 | -$411,057,619 | -$97,262,601 | PRTA, APLS, SRPT, ANAB, ARVN | 13F-HR | 14 Nov 2022, 11:07 |
| Q2 2022 | 78 | $2,873,148,000 | +$541,955,101 | -$313,188,658 | +$228,766,443 | PRTA, APLS, SRPT, SGEN, GLPG | 13F-HR | 15 Aug 2022, 11:14 |
| Q1 2022 | 86 | $3,190,131,000 | +$1,133,396,163 | -$459,126,069 | +$674,270,094 | PRTA, APLS, GLPG, ANAB, SRPT | 13F-HR | 16 May 2022, 09:42 |
| Q4 2021 | 75 | $3,123,752,000 | +$755,741,732 | -$259,955,349 | +$495,786,383 | PRTA, ANAB, RCUS, XNCR, APLS | 13F-HR | 14 Feb 2022, 09:56 |
| Q3 2021 | 69 | $2,830,876,000 | +$362,380,058 | -$329,529,622 | +$32,850,436 | PRTA, MORF, ANAB, RCUS, XNCR | Restatement | 22 Nov 2021, 13:52 |
| Q2 2021 | 72 | $2,663,196,000 | +$401,848,061 | -$61,496,137 | +$340,351,924 | PRTA, MORF, ANAB, XNCR, RLAY | 13F-HR | 16 Aug 2021, 11:11 |
| Q1 2021 | 70 | $2,233,218,000 | +$556,418,132 | -$153,166,016 | +$403,252,116 | PRTA, XNCR, MORF, ANAB, NUVB | 13F-HR | 17 May 2021, 10:53 |
| Q4 2020 | 63 | $1,792,534,000 | +$514,934,432 | -$312,164,648 | +$202,769,784 | XNCR, RLAY, STTK, SPRY, PRTA | 13F-HR | 16 Feb 2021, 10:30 |
| Q3 2020 | 44 | $1,385,947,000 | +$337,839,097 | -$290,744,841 | +$47,094,256 | XNCR, KURA, RLAY, PRTA, MORF | 13F-HR | 16 Nov 2020, 10:47 |
| Q2 2020 | 46 | $1,335,460,000 | +$557,358,297 | -$426,981,755 | +$130,376,542 | XNCR, PRTA, ORIC, MORF, KURA | 13F-HR | 14 Aug 2020, 10:59 |
| Q1 2020 | 51 | $957,232,000 | +$243,568,551 | -$168,955,039 | +$74,613,512 | PRTA, XNCR, ARVN, DRNA, FATE | 13F-HR | 15 May 2020, 16:07 |
| Q4 2019 | 42 | $1,054,034,000 | +$335,271,820 | -$227,448,289 | +$107,823,531 | PRTA, XNCR, DRNA, FGEN, KURA | Restatement | 18 Feb 2020, 16:31 |
| Q3 2019 | 35 | $749,426,000 | +$172,079,366 | -$250,317,386 | -$78,238,020 | XNCR, PRTA, ONCE, KURA, ARGX | 13F-HR | 14 Nov 2019, 16:15 |
| Q2 2019 | 37 | $970,382,000 | +$230,608,347 | -$244,400,465 | -$13,792,118 | KURA, XNCR, ARGX, CRSP, FGEN | 13F-HR | 14 Aug 2019, 16:49 |
| Q1 2019 | 36 | $923,849,000 | +$234,167,803 | -$408,778,834 | -$174,611,031 | ARGX, KURA, MRTX, CRSP, XNCR | 13F-HR | 15 May 2019, 16:21 |
| Q4 2018 | 46 | $869,349,000 | +$344,265,853 | -$207,267,747 | +$136,998,106 | ARGX, KURA, FGEN, IRWD, ASMB | 13F-HR | 14 Feb 2019, 16:15 |
| Q3 2018 | 41 | $966,248,000 | +$206,250,590 | -$190,487,717 | +$15,762,873 | FGEN, ASMB, IRWD, ASND, KURA | 13F-HR | 14 Nov 2018, 16:53 |
| Q2 2018 | 27 | $914,687,000 | +$244,793,729 | -$285,726,708 | -$40,932,979 | FGEN, IRWD, ASMB, ASND, KURA | 13F-HR | 14 Aug 2018, 12:11 |
| Q1 2018 | 27 | $933,286,000 | +$186,502,567 | -$94,068,652 | +$92,433,915 | ASMB, ASND, FGEN, IRWD, KURA | 13F-HR | 15 May 2018, 16:07 |
| Q4 2017 | 24 | $745,714,000 | +$190,933,013 | -$198,692,171 | -$7,759,158 | ASMB, FGEN, IRWD, ASND, KURA | 13F-HR | 14 Feb 2018, 13:50 |
| Q3 2017 | 37 | $730,261,000 | +$266,829,339 | -$104,606,521 | +$162,222,818 | ASMB, FGEN, IRWD, ASND, KURA | 13F-HR | 14 Nov 2017, 16:25 |
| Q2 2017 | 32 | $433,545,000 | +$164,187,256 | -$69,458,601 | +$94,728,655 | IRWD, ASMB, FGEN, GLPG, ASND | 13F-HR | 14 Aug 2017, 16:25 |
| Q1 2017 | 31 | $361,177,000 | +$78,645,744 | -$89,217,032 | -$10,571,288 | ASMB, IRWD, GLPG, ASND, KURA | Restatement | 19 May 2017, 12:39 |
| Q4 2016 | 1 | $0 | $0 | $0 | $0 | New Holdings | 15 Feb 2017, 16:59 | |
| Q4 2016 | 29 | $288,479,000 | +$108,957,289 | -$87,215,724 | +$21,741,565 | IRWD, GLPG, ASMB, ALXN, ASND | Restatement | 15 Feb 2017, 16:56 |
| Q3 2016 | 25 | $261,623,000 | +$94,392,508 | -$84,500,837 | +$9,891,671 | IRWD, GLPG, ASMB, DERM, ARDX | 13F-HR | 14 Nov 2016, 16:34 |
| Q2 2016 | 27 | $219,175,000 | +$63,988,183 | -$95,130,260 | -$31,142,077 | IRWD, GLPG, RTRX, CYTK, ASMB | 13F-HR | 15 Aug 2016, 12:02 |
| Q1 2016 | 30 | $246,572,000 | +$101,303,249 | -$42,130,960 | +$59,172,289 | IRWD, FPRX, EPZM, FGEN, ARRAY BIOPHARMA INC | 13F-HR | 16 May 2016, 16:14 |
| Q4 2015 | 25 | $248,392,633 | +$92,704,360 | -$75,757,372 | +$16,946,988 | FGEN, FPRX, RTRX, KURA, ASMB | 13F-HR | 16 Feb 2016, 10:48 |
| Q3 2015 | 22 | $216,168,000 | +$38,915,465 | -$21,103,967 | +$17,811,498 | FGEN, ATRA, ARRAY BIOPHARMA INC, RTRX, EPZM | 13F-HR | 16 Nov 2015, 11:51 |
| Q2 2015 | 21 | $283,588,000 | +$61,803,216 | -$70,674,972 | -$8,871,756 | ATRA, EPZM, ASMB, FGEN, ARRAY BIOPHARMA SR CONV NT 3.000% Due 06/01/2020 | 13F-HR | 14 Aug 2015, 10:30 |
| Q1 2015 | 19 | $267,814,000 | +$98,741,425 | -$47,171,141 | +$51,570,284 | ATRA, EPZM, RCPT, ARRAY BIOPHARMA SR CONV NT 3.000% Due 06/01/2020, ASMB | Restatement | 15 May 2015, 18:27 |
| Q4 2014 | 19 | $177,568,000 | $0 | $0 | $0 | KITE, CLVSQ, RCPT, ARRAY BIOPHARMA INC, MGNX | 13F-HR | 17 Feb 2015, 16:13 |